Poland· PL-100101034
Eziclen
A osmotically acting laxatives product containing natrii sulfas anhydricus + magnesii sulfas heptahydricus + kalii sulfas, registered in Poland by MAYOLY PHARMA FRANCE. The same ATC class is registered in 6 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Natrii sulfas anhydricus + magnesii sulfas heptahydricus + kalii sulfas is registered in 6 of 19 countries.
Countries holding a registration under ATC A06AD (osmotically acting laxatives), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Natrii sulfas anhydricus + magnesii sulfas heptahydricus + kalii sulfas · ATC A06AD
6 / 19 countries
- Belgiumprice
- Denmark
- Ireland
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Natrii sulfas anhydricus + Magnesii sulfas heptahydricus + Kalii sulfas
- Manufacturer
- MAYOLY PHARMA FRANCE
- Country
- Poland (PL)
- ATC code
- A06AD
- ATC class
- Osmotically acting laxatives
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991058340
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Natrii sulfas anhydricus + magnesii sulfas heptahydricus + kalii sulfas in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesSodium sulfate, potassium sulfate and magnesium sulfateNorthStar RxLLC
- United KingdomPotassium chloride 0.15% (potassium 20mmol/1litre) / Magnesium sulfate 0.2% (magnesium 8mmol/1litre) / Sodium chloride 0.9% infusion 1litre bagsSpecial Order
- FranceIZINOVA, solution à diluer pour solution buvableMAYOLY PHARMA FRANCE
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf1ecb8d-4c69-4bfe-ac4b-9fbb0b04229c GET /v1/drugs/bf1ecb8d-4c69-4bfe-ac4b-9fbb0b04229c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu doustnego",
"source": "urpl",
"strength": "(17,51 g + 3,276 g + 3,13 g)/butelkę",
"packaging": "05909991058340 ¦ Rp ¦ 83886\n1 butelka 176 ml ¦ 1 butelka 176 ml ¦ 1 kubek",
"substance": "Natrii sulfas anhydricus 17,510 g/butelkę + Magnesii sulfas heptahydricus 3,276 g/butelkę + Kalii sulfas 3.13 g + Kalii sulfas 3,13 g/butelkę + Magnesii sulfas 3.276 g + Natrii sulfas anhydricus 17.51 g",
"common_name": "Natrii sulfas anhydricus + Magnesii sulfas heptahydricus + Kalii sulfas",
"pl_product_id": "100101034",
"pozwolenie_nr": "21110",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about natrii sulfas anhydricus + magnesii sulfas heptahydricus + kalii sulfas.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.